Literature DB >> 21672534

Reference intervals for serum creatinine with enzymatic assay and evaluation of four equations to estimate glomerular filtration rate in a healthy Chinese adult population.

XueJing Wang1, GuoBin Xu, HaiXia Li, Yan Liu, Fang Wang.   

Abstract

BACKGROUND: With the wide usage of enzymatic assays to determine serum creatinine (Scr) in China, reference interval (RI) needs to be established. At the same time, the performance of Scr based equations to calculate estimated glomerular filtration rate (eGFR) in healthy Chinese adults has not been extensively investigated.
METHODS: This study has strictly followed the International Federation of Clinical Chemistry (IFCC) recommendations and the Clinical Laboratory Standards Institute (CLSI) C28-A2 document. A total number of 778 healthy Chinese adults (male 433, female 345) were enrolled in this study.
RESULTS: By nonparametric method, RIs for males were: <60 years, 58-93 μmol/l and >60 years, 54-109 μmol/l; RIs for females were: <60 years, 42-69 μmol/l and >60 years, 43-83 μmol/l. Modification of Diet in Renal Disease (MDRD) equation and MDRD for Japanese made the percentage of eGFR >90 ml/min/1.73 m(2) 31.7% and 4.9%; percentage of eGFR 60-89 ml/min/1.73 m(2) 65.2% and 64.0%, respectively. Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation and CKD-EPI for Asian made the percentage of eGFR >90 ml/min/1.73 m(2) 89.2% and 94.0%; percentage of eGFR 60-89 ml/min/1.73 m(2) 10.3% and 5.7%, respectively.
CONCLUSION: Scr RIs of healthy Chinese adults were found to be lower than those of Caucasians. Two MDRD equations underestimated GFR, while two CKD-EPI equations seemed to estimate a reasonable distribution of eGFR in healthy Chinese adult populations.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21672534     DOI: 10.1016/j.cca.2011.05.033

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  6 in total

1.  Effect of low-dose diuretics on the level of serum cystatin C and prognosis in patients with asymptomatic chronic heart failure.

Authors:  Yuan Zhang; Yanming Li; Guanchang Cheng
Journal:  Exp Ther Med       Date:  2015-10-30       Impact factor: 2.447

2.  Reference intervals for total bilirubin, ALT, AST and creatinine in healthy Chinese elderly.

Authors:  Guo-ming Zhang; Yong-jie Xia; Xu-xiao Guo; Bao-lin Zhu; Gao-ming Zhang; Xiao-bo Ma; Hong Yu; Hong-jian Wang; Guang-sheng Wang; Li Yang; Ye-ting Zhou
Journal:  Med Sci Monit       Date:  2014-10-01

3.  Reference intervals for serum cystatin C and serum creatinine in an adult sub-Saharan African population.

Authors:  Bertille Elodie Edinga-Melenge; Adrienne Tchapmi Yakam; Jobert Richie Nansseu; Catherine Bilong; Suzanne Belinga; Eric Minkala; Prisca Armel Noudjeu; Michel Ondhoua; Samuel Walter Kokola; Vicky Joceline Ama Moor; Gloria Ashuntantang
Journal:  BMC Clin Pathol       Date:  2019-03-18

4.  Correction of serum NSE reference intervals includes the unidentified hemolysis sample: 1-year data analysis from healthcare individuals.

Authors:  Erfu Xie; Wei Zhang; Huaguo Xu; Yun Ling; Qiaodi Zhang; Shiyang Pan
Journal:  J Clin Lab Anal       Date:  2019-08-11       Impact factor: 2.352

5.  Multicenter study of creatinine- and/or cystatin C-based equations for estimation of glomerular filtration rates in Chinese patients with chronic kidney disease.

Authors:  Jia-fu Feng; Ling Qiu; Lin Zhang; Xue-mei Li; Yu-wei Yang; Ping Zeng; Xiu-zhi Guo; Yan Qin; Hong-chun Liu; Xing-min Han; Yan-peng Li; Wei Xu; Shu-yan Sun; Li-qiang Wang; Hui Quan; Li-jun Xia; Hong-zhang Hu; Fang-cai Zhong; Rong Duan
Journal:  PLoS One       Date:  2013-03-19       Impact factor: 3.240

6.  Association between kidney function and Framingham global cardiovascular disease risk score: a Chinese longitudinal study.

Authors:  Bo Jin; Xiaojuan Bai; Lulu Han; Jing Liu; Weiguang Zhang; Xiangmei Chen
Journal:  PLoS One       Date:  2014-01-20       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.